Methylene blue is a drug, not a supplement

Most of what I write in this beat follows the same shape: a supplement makes a claim, and I go find out whether the study behind it says what the label says it does. Usually the answer is that a real but modest finding got stretched.

Methylene blue is a different case, and it needs a different treatment. The issue is not that the evidence is thinner than advertised, though it is. The issue is a category error sitting underneath the whole conversation.

This molecule is not a botanical that someone decided to study. It is a synthetic dye, first made in the 1870s, that became a pharmaceutical. It has an approved prescribing label. And the fastest way to understand what is actually known about it is to stop reading wellness content and read that label, which is a public document that anybody can open.

So I opened it.

What is actually approved

The product is PROVAYBLUE, methylene blue injection, manufactured for Provepharm and distributed by American Regent. The label I read was revised in February 2024. Its indications section is one sentence long, verbatim:

PROVAYBLUE is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.

That is the entire approved use. Methemoglobinemia is a condition where hemoglobin gets chemically stuck in a form that cannot release oxygen to tissue. It is uncommon, it is often triggered by exposure to a specific drug or chemical, and it is an emergency. Methylene blue works there by acting as a redox shuttle that converts the iron in hemoglobin back to the form that carries oxygen. It is a genuinely good drug for this. It is close to an antidote.

The dosing section, verbatim: "Administer PROVAYBLUE 1 mg/kg intravenously over 5-30 minutes."

Intravenously. Over five to thirty minutes. In a setting where someone is watching a patient who is acutely ill.

Nothing on that label concerns energy, focus, brain fog, mitochondrial support, longevity, or cognition. Those are not off-label extensions of an approved use. They are a separate set of claims with no approved indication behind them at all.

The two warnings that travel badly

Here is where the category error stops being academic.

Serotonergic interaction. The label's warning, verbatim: "Avoid concomitant use of PROVAYBLUE with serotonergic drugs and opioids...Inform patients of the increased risk of serotonin syndrome and advise them to not to take serotonergic drugs within 72 hours after the last dose of PROVAYBLUE."

Read the class list on that. SSRIs, SNRIs, MAOIs, opioids. Between antidepressants and pain medication, that is an enormous fraction of the adult population, and it includes a lot of people who would never describe themselves as "on a serotonergic drug," because what they would say is that they take something for anxiety.

Note also the 72-hour washout. That is not a routine caution. Labels do not instruct patients to avoid an entire drug class for three days after a dose over a theoretical concern. Serotonin syndrome, at its severe end, is a medical emergency.

G6PD deficiency. The contraindication, verbatim: "PROVAYBLUE is contraindicated in...Patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of hemolytic anemia."

Contraindicated is the strongest word in the vocabulary. Not "use caution," not "monitor." Do not give this.

G6PD deficiency is an inherited enzyme condition, and it is not rare worldwide. Most people who have it feel completely normal and will never know until something oxidative stresses their red blood cells. It is found by a specific blood test that is not part of a standard panel. If you have never been tested, you do not know your status, and neither does the person selling you drops.

This is the part of the story that has nothing to do with whether the molecule works. In the approved setting, both risks are managed by a clinician who has the chart, knows the medication list, can order a G6PD test, and is watching for a reaction. Take the same molecule out of that setting and every one of those controls is gone while the pharmacology stays exactly where it was.

What the human cognitive evidence actually is

Now to the claim itself, fairly, because there is a real study here and it deserves to be described accurately rather than dismissed.

Rodriguez and colleagues, in Radiology in 2016, ran a randomized, double-blinded, placebo-controlled functional MRI study. Twenty-six subjects, aged 22 to 62. They imaged the brain during a sustained-attention task and a short-term-memory task, before and one hour after a single low dose of methylene blue or placebo.

The result, verbatim: "Methylene blue was also associated with a 7% increase in correct responses during memory retrieval (P = .01)." The conclusion, verbatim: "Low-dose methylene blue can increase functional MR imaging activity during sustained attention and short-term memory tasks and enhance memory retrieval."

That is a real, positive, randomized finding, published in a serious journal, and I am not going to wave it away. It is also, precisely, this: twenty-six people, one dose, one hour, one behavioral outcome, alongside brain-imaging changes.

What it does not establish is what people are actually doing. It says nothing about taking this daily for months. Nothing about a benefit you would notice in your life rather than in a task inside a scanner. Nothing about who should not take it. Nothing about what happens on dose two hundred.

A single small acute study is a reason to run a bigger one. It is not a reason to start a daily protocol, and the distance between those two things is where most of this industry lives. I made the same argument about NMN's blood-marker evidence: the study measured a real thing, and the real thing measured was not the thing being sold.

The largest test of this chemistry, and how it ended

There is a piece of evidence the wellness coverage almost never mentions, and it is by far the biggest.

Methylene blue's core, the methylthioninium moiety, was developed into an actual drug candidate for Alzheimer's disease on the theory that it inhibits tau protein aggregation. The compound, LMTM, is described in its own trial publication as "a stable reduced form of the methylthioninium moiety." It went into a full phase 3 program.

Gauthier and colleagues published the trial in The Lancet in 2016. It was randomized, double-blind, 15 months long, across 115 centers in 16 countries, with 891 participants across three arms.

The finding, verbatim: "The prespecified primary analyses did not show any treatment benefit at either of the doses tested for the coprimary outcomes."

And the interpretation, verbatim: "The primary analysis for this study was negative, and the results do not suggest benefit of LMTM as an add-on treatment for patients with mild to moderate Alzheimer's disease."

Be precise about what this does and does not prove. LMTM is a modified, stabilized form of the molecule, not methylene blue off a shelf. The population was Alzheimer's patients, not healthy adults. The outcome was disease progression, not focus on a Tuesday afternoon. A negative result there does not formally refute a cognitive effect in healthy people, and I will not claim it does.

But consider what it represents. This is the scenario supplement evidence almost never gets: a serious, well-funded, adequately powered, long-duration test of the chemistry, run by people with every incentive to find an effect. They ran it properly and it did not work.

Set the two studies side by side. Twenty-six people for one hour, positive. Eight hundred ninety-one people for fifteen months, negative. Only the first one shows up in the marketing.

Where the regulatory question actually sits

I want to be careful here, because this is the claim I saw asserted most confidently online and could verify least.

What I can state from documents I opened: there is one FDA-approved methylene blue product I examined, it is an injection, and it is approved for acquired methemoglobinemia and nothing else. StatPearls, the peer-reviewed clinical reference in the National Library of Medicine's bookshelf, updated 2 January 2026, describes it the same way: the "Food and Drug Administration–approved treatment for acquired methemoglobinemia."

What I could not verify: several pages assert that the FDA has formally determined methylene blue cannot lawfully be a dietary ingredient, or that specific warning letters exist saying so. Every page making that claim was a vendor, a marketing blog, or an AI-generated health site. I could not find a primary agency document stating it, so I am not asserting it, and neither should anything you read that cannot show you the letter.

The distinction is worth holding onto, because you do not need the regulatory question resolved to make a decision. The pharmacology does not check your product's legal classification before it interacts with your antidepressant.

The questions I would ask

Do I know my G6PD status? If you have never had the specific test, the answer is no. This is a documented contraindication, not a theoretical one, and it is invisible without testing.

What else am I taking? Antidepressants, migraine medication, tramadol, dextromethorphan in a cough syrup. The approved label instructs a 72-hour separation from serotonergic drugs. Whatever you think of the dose difference, the interaction is the reason that sentence is on a federal document.

What is in the bottle, and how would I know? The approved product is a pharmaceutical-grade injectable made under drug manufacturing rules. A product sold outside that framework carries no equivalent guarantee, and methylene blue also exists in industrial and aquarium grades. I did not test any specific product and I am not accusing any specific seller, but "same molecule" and "same purity" are separate claims, and only one of them is easy to make. I went through what independent testing actually finds in the supplement aisle in an earlier report.

Is my evidence one small study? If the honest answer is a single acute trial in twenty-six people, that is a hypothesis, and you are the experiment.

The signal

The framing to carry out of here is not "methylene blue is dangerous," which is too blunt to be useful. In a hospital, given correctly, it is a good drug that saves people.

The framing is that a molecule's risk profile does not change when its packaging does. Everything on that label, the interaction warning, the washout period, the contraindication, is a description of what this compound does inside a human body. Those facts were established because it is a drug, studied as a drug, given by clinicians who could observe what happened. Sell the same chemistry in a dropper bottle and none of the pharmacology relaxes. What goes away is the person who was watching.

That is the general rule, and it outlives this particular blue molecule. When something crosses from the pharmacy into the wellness aisle, ask what was left behind in the move. Usually it is not the mechanism. It is the monitoring.

Not medical advice. This is educational analysis, not a recommendation — a study is not a prescription. Talk to a qualified clinician before acting on anything you read here. Full disclaimer →

Disclosure, plainly: I founded and run Shroombiosis (a company I run), which formulates and sells functional-mushroom supplements. That is a direct commercial stake in the industry this report is about, and I want to be honest about which way it cuts here: methylene blue is not a category I sell into, so nothing in this report costs me anything, and you should weigh it accordingly. The rule at the end applies to my own products as much as to anyone's, and the fair test of a formulator is whether the same standard survives contact with his own shelf. Nothing here is sponsored and no link earns a commission; here's the full policy. A recommendation with no stake at all: for performance nutrition, Die Tryin Co. is a fellow combat-veteran-owned brand I'm glad to point people to. I don't own it and earn nothing from the link.